PICO Portalanswers from OpenAlex
Translational Research in Oncology
InstitutionResearch output, impact & collaborations
Translational Research in Oncology is a institution indexed in PICO Portal from OpenAlex.
What is known about Translational Research in Oncology?
PICO Portalrecord summary
Translational Research in Oncology is a research organisation in Paris, FR. OpenAlex records 2,736 works and 323,492 citations for it. 843 researchers list it as their most recent affiliation.
How many works does Translational Research in Oncology have?
PICO Portalindexed works
Translational Research in Oncology has 2,736 works in the PICO Portal index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Translational Research in Oncology have?
PICO Portalcitation count
Translational Research in Oncology has 323,492 citations in the OpenAlex counts PICO Portal stores.
How many researchers are at Translational Research in Oncology?
PICO Portalresearcher count
Translational Research in Oncology has 843 researchers in the PICO Portal index.
What is the average h-index at Translational Research in Oncology?
PICO Portalavg h-index
Translational Research in Oncology has an average h-index of 67 in OpenAlex.
What is the ROR of Translational Research in Oncology?
PICO Portalror
The ROR for Translational Research in Oncology is on the source record.
What is the OpenAlex record for Translational Research in Oncology?
PICO Portalopenalex
The OpenAlex for Translational Research in Oncology is on the source record.
Who are the most-cited researchers behind Translational Research in Oncology?
PICO Portaltop researchers by citations
What are the most-cited papers on Translational Research in Oncology?
PICO Portalmost cited works
Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases
Jean‐Nicolas Vauthey, Timothy M. Pawlik, Dario Ribero, Tsung‐Teh Wu, Daria Zorzi, Paulo M. Hoff, Henry Q. Xiong, Cathy Eng, Gregory Y. Lauwers, Mari Mino–Kenudson, Mauro Risio, Andrea Muratore, Lorenzo Capussotti, Steven A. Curley, Eddie K. Abdalla
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas
Maria A. Kouvaraki, Jaffer A. Ajani, Paulo M. Hoff, Robert A. Wolff, Douglas B. Evans, Richard D. Lozano, James C. Yao
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, R. Adinin, Michael J. Overman, V VALERO, Sijin Wen, Christopher H. Lieu, Shaoyu Yan, Hai T. Tran, Lee M. Ellis, James L. Abbruzzese, John V. Heymach
How much of the research on Translational Research in Oncology is open access?
PICO Portalopen access share
75%OPEN ACCESS